Companies

BECTON DICKINSON & CO

BDX · CIK 0000010795 · operating

$173.67-1.59%Last updated Mar 2, 4:46 PM

Key Statistics

Valuation

Market Cap$63.06B
P/E28.44
Fwd P/E12.90
PEG
P/S2.88
P/B1.96
EV/EBITDA11.43
EV/Rev3.15

Profitability

Gross Margin
Op. Margin11.81%
Net Margin7.68%
ROE6.61%
ROA3.03%
FCF Margin

Financial Health

Current Ratio1.11
Debt/Equity
Free Cash Flow
Div. Yield2.38%

Growth & Other

Revenue Growth8.24%
EPS Growth-0.68%
Beta0.28
52W High$187.35
52W Low$127.586

About BECTON DICKINSON & CO

Becton, Dickinson and Company manufactures and distributes medical supplies, devices, laboratory equipment, and diagnostic products for use across healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers globally. The company's product portfolio spans peripheral and central vascular access devices, infusion therapy systems, hypodermic syringes and needles, sharps disposal systems, specimen collection products, and drug delivery systems. It also produces automated laboratory equipment for blood and microbial culturing, molecular diagnostics, and flow cytometry instruments alongside associated reagents and consumables.

The company operates through four primary segments. Medical Essentials encompasses vascular access, infusion therapy, and medication safety products. Connected Care includes medication dispensing automation, pharmacy informatics, and hemodynamic monitoring systems. BioPharma Systems provides prefillable drug delivery systems and advanced laboratory diagnostic tools. Interventional and Life Sciences covers surgical products, tissue repair solutions, and diagnostic reagents for oncology and immunology applications.

Becton Dickinson employs approximately 70,000 full-time employees and maintains operations worldwide, serving customers across North America, Europe, and international markets. The company was founded in 1897 and is incorporated in New Jersey with headquarters in Franklin Lakes.

Earnings Per Share (Annual · SEC XBRL)

Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.

Fiscal YearEPS DilutedEPS BasicYoY
2025$5.82$5.83-0.7%
2024$5.86$5.88+18.6%
2023$4.94$4.97-16.0%
2022$5.88$5.93-14.2%
2021$6.85$6.92+1802.8%
2020$0.36$0.36-20.0%
2019$0.45$0.46+170.3%
2018$-0.64$-0.64-151.6%
2017$1.24$1.27+1277.8%
2016$0.09$0.09-89.3%
2015$0.84$0.86-86.0%
2014$5.99$6.13-7.7%
2013$6.49$6.63+16.1%
2012$5.59$5.69-0.5%
2011$5.62$5.75+2.4%
2010$5.49$5.62+10.0%
2009$4.99$5.12

Annual Reports (10-K) · 9 filings

Report DateFiledAccession Number
2025-09-302025-11-250000010795-25-000099SEC ↗
2024-09-302024-11-270000010795-24-000084SEC ↗
2023-09-302023-11-210000010795-23-000098SEC ↗
2022-09-302022-11-220001628280-22-030686SEC ↗
2021-09-302021-11-240000010795-21-000091SEC ↗
2020-09-302020-11-250000010795-20-000055SEC ↗
2019-09-302019-11-270000010795-19-000044SEC ↗
2018-09-302018-11-210000010795-18-000036SEC ↗
2017-09-302017-11-220000010795-17-000021SEC ↗